OSE Immunotherapeutics Updates on Anti-IL-7 Receptor Antagonist OSE-127/S95011, a Breakthrough Approach in Chronic Inflammatory Autoimmune Diseases and Hematology· Positive Phase 1 clinical results published in 'The Journal of Immunology’ (online)· &.
Positive Phase 1 clinical results published in 'The Journal of Immunology' (online) Two ongoing Phase 2 clinical trials in Ulcerative Colitis and primary Sjögren's Syndrome Positive
Vera Therapeutics Inc. (VERA) Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland – October 25, 2022Idorsia Ltd (SIX: IDIA) today announced its financial results for the.
11.08.2022 - -Sabizabulin for COVID-19 Emergency Use Authorization Application Submitted to U.S. FDA in June 2022- -The UK’s Medicines and Healthcare Products Regulatory Agency Informed the Company that its Sabizabulin Marketing Authorization Application Will .